Shots:
Recently Pheast Therapeutics shared the preclinical data for PHST001, an anti-CD24 macrophage checkpoint inhibitor at the 20th Annual PEGS Boston Summit
Today, at PharmaShots, we had a dialogue exchange with Roy Maute, Cofounder and CEO of Pheast Therapeutics
Pheast Therapeutics currently plans to initiate a clinical trial in H1’25
Saurabh: Can you walk me…
